Maypharm, a leading South Korean innovator in medical and dermo-cosmetic solutions, has launched Hyalmass Aqua-Exosome, a hybrid mesotherapy filler designed to meet the growing demands of aesthetic medicine. This groundbreaking product combines hyaluronic acid, exosomes, and polydeoxyribonucleotide (PDRN) to address key skin concerns such as hydration, elasticity, and regeneration—marking a significant first in the world of aesthetic treatments.
Maypharm Introduces Hyalmass Aqua-Exosome: A Hybrid Filler for Enhanced Hydration and Regeneration sets itself apart from conventional hydration fillers by incorporating regenerative components. Exosomes, derived from human stem cell-conditioned media and plants, as well as PDRN, work synergistically to stimulate collagen and elastin production. These ingredients enhance fibroblast activity, offering long-term skin rejuvenation that goes beyond surface-level hydration.
The launch of Maypharm Introduces Hyalmass Aqua-Exosome: A Hybrid Filler for Enhanced Hydration and Regeneration comes at a crucial juncture in the aesthetics industry, as non-invasive procedures continue to dominate. According to the American Society of Plastic Surgeons (ASPS), minimally invasive treatments experienced a 7% growth in 2023, surpassing the growth of traditional surgical procedures. The surge in popularity of injectables like dermal fillers and neuromodulators demonstrates the industry’s shift toward more accessible, low-risk alternatives to invasive surgery, with over 25 million non-invasive cosmetic treatments performed last year.
Formulated with a blend of active ingredients, Hyalmass Aqua-Exosome offers a holistic approach to skin health. Hyaluronic acid provides immediate hydration, exosomes enhance cellular regeneration and communication, and PDRN supports tissue repair and skin elasticity. Together, these ingredients deliver a multi-faceted solution to visibly smoother, plumper, and revitalized skin, addressing both surface hydration and deeper regenerative needs.
Manufactured by Beauty Factory, a trusted medical aesthetics manufacturer in South Korea, Hyalmass Aqua-Exosome adheres to stringent international Good Manufacturing Practice (GMP) guidelines. The filler is produced in collaboration with academic research institutions and global partners, which contribute to its innovative formulation. The product is packaged in prefilled syringes to ensure hygiene and convenience, while the high-purity, high-molecular-weight formula offers extended efficacy.
To maintain consistent quality and safety, Beauty Factory employs a seven-step quality control system to thoroughly test all products for reliability and consistency, ensuring that each treatment meets the highest standards in both safety and performance.
